TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02878681
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 mg intravitreal injections
Study: NCT00129597
Drug: ketalar
Normalized name: Ketalar
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02368886
Drug: Clobetasol Propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given topically
Study: NCT00407212
Drug: TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)
Normalized name: (R)-indan-1-yl-prop-2-ynyl-amine
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02368886
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT03465111
Drug: ACTH (adrenocorticotropic hormone) gel
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dose of H.P. Acthar Gel is 80 Units administered subcutaneously
Study: NCT00550732
Drug: Posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole oral suspension was administered as 400 mg twice daily (bis in die, BID) with food or 200 mg four times daily (quater in die, QID) without food for a minimum of 1 month.
Study: NCT00415155
Drug: LY2181308
Normalized name: LY2181308
DrugBank: LY2181308 (DB05141)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1: 250mg, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle. (dose escalation)~Phase 2: phase 1 recommended dose, maximum 750mg dose, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle.
Study: NCT01381120
Drug: Solifenacin succinate treatment
Normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage form: tablet, film coated Dosage: 5 mg Frequency: daily Duration: three months
Study: NCT03132714
Drug: Amoxicillin 500mg
Normalized name: AMOXICILLIN 500MG CAP
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of Amoxicillin 500mg tid for 7 days
Study: NCT03132714
Drug: Metronidazole 400mg
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of Metronidazole 400mg tid for 7 days.
Study: NCT00081107
Drug: epothilone D
Normalized name: Epothilone D
DrugBank: Epothilone D (DB01873)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00891813
Drug: Zemplar (paricalcitol)
Normalized name: paricalcitol Injection [Zemplar]
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zemplar (paricalcitol) dose will be calculated mcg=PARATHYROID HORMONE level/100; this will be provided 3 times per week. Dose will be adjusted by 2-4 mcg every 4 weeks according to the parathyroid hormone level.
Study: NCT00355667
Drug: furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with chronic heart failure receive furosemide and other standard treatment/
Study: NCT00355667
Drug: azosemide
Normalized name: azosemide
DrugBank: Azosemide (DB08961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with chronic heart failure receive azosemide and other standard treatment.
Study: NCT04410406
Drug: Ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin (IVM) 200 µg/kg
Study: NCT04410406
Drug: Diethylcarbamazine
Normalized name: Diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylcarbamazine (DEC) 6mg/kg
Study: NCT04410406
Drug: Albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole (ABZ) 400 mg
Study: NCT04410406
Drug: Moxidectin
Normalized name: moxidectin
DrugBank: Moxidectin (DB11431)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxidectin (Mox) 8 mg
Study: NCT02083640
Drug: Palbociclib Formulation Reference
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125 mg single dose of palbociclib formulation with 16 micrometer API particle size and dissolution level 1, which is representative of the intended commercial hard gelatin capsule.
Study: NCT02083640
Drug: Palbociclib Formulation Test
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125 mg single dose of palbociclib formulation with 41 micrometer API particle size and dissolution level 1
Study: NCT02083640
Drug: Palbociclib Formulation Test
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125 mg single dose of palbociclib formulation with 16 micrometer API particle size and dissolution level 2
Study: NCT00305760
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab will be administered at an initial dose of 400 mg/m2, followed by weekly doses of 250 mg/m2 for a total of 6 cycles that last 3 weeks each.
Study: NCT00180674
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02194218
Drug: Nevirapine, low dose
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg
Study: NCT02194218
Drug: Nevirapine, high dose
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg
Study: NCT02536690
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.
Study: NCT02536690
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Remifentanil 0.25 mcg/kg/min infusion for 5 min before propofol administration followed by midazolam 0.03 mg/kg administration 1 min after remifentanil infusion start.
Study: NCT01192490
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5cc of 2% Lidocaine gel will be placed on the cervix and intra-cervically prior to placement of a Mirena
Study: NCT02490930
Drug: Fingolimod
Normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral fingolimod will be given 1 week prior to the initiation of concurrent radiation and temozolomide and will be discontinued immediately upon completion of the six weeks of therapy.
Study: NCT04428086
Drug: Apatinib in arm1
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib will be administered at a dose of 250 mg once daily from Day 4 to Day 9.
Study: NCT04428086
Drug: Apatinib in arm2
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib will be administered at a dose of 250 mg once daily from Day 3 to Day 7.
Study: NCT04428086
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin will be administered as a single oral 500 mg on Day 1 and Day 6.
Study: NCT00624143
Drug: ORAL VORICONAZOLE and IV Amphotericin B
Normalized name: Amphotericin B
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Voriconazole will be given in dose of 6mg/kg 12 hourly on day1 then 4mg/kg 12 hourly daily or IV Amphotericin B 0.5 mg/kg/day weekly thrice till the completion of induction or recovery of ANC \>1000/MM3 or development of fungal infection
Study: NCT01553123
Drug: Ulipristal Acetate
Normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: once daily, oral
Study: NCT01501760
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Three subconjunctival injections of 0.5 ml of bevacizumab at: inclusion, 1 month, 2 month
Study: NCT01501760
Drug: NaCl
Normalized name: NaCl
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Three subconjunctival injections 0.5 ml placebo (Balanced salt) solution at inclusion, 1 month, 2month
Study: NCT04289285
Drug: IBI306 450mg SC Q4W
Normalized name: Immunoglobulin igg2, anti-(human proprotein convertase subtilisin/kexin type 9) (human monoclonal ibi306 .gamma.2-chain), disulfide with human monoclonal ibi306 .kappa.-chain, dimer
DrugBank: Tafolecimab (DB16336)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive IBI306 450mg every 4 weeks subcutaneously.
Study: NCT04289285
Drug: IBI306 600mg SC Q6W
Normalized name: Immunoglobulin igg2, anti-(human proprotein convertase subtilisin/kexin type 9) (human monoclonal ibi306 .gamma.2-chain), disulfide with human monoclonal ibi306 .kappa.-chain, dimer
DrugBank: Tafolecimab (DB16336)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive IBI306 600mg every 6 weeks subcutaneously.
Study: NCT02096081
Drug: IncobotulinumtoxinA
Normalized name: incobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points; mode of application: intramuscular injection
Study: NCT02096081
Drug: OnabotulinumtoxinA
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points; mode of application: intramuscular injection
Study: NCT00055523
Drug: Adalimumab (D2E7)
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00000263
Drug: 30% Nitrous oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00648817
Drug: Tenofovir Disoproxil Fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil)
Study: NCT02026349
Drug: favipiravir
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Administered twice daily over 5 consecutive days for a total of 10 doses.~* Day 1: 1800 mg twice daily (loading doses)~* Days 2 through 5: 800 mg twice daily
Study: NCT00635505
Drug: albuterol HFA (Armstrong's)
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mcg QID 12 weeks
Study: NCT00635505
Drug: albuterol HFA (Proventil HFA)
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mcg QID 12 weeks
Study: NCT04105985
Drug: Articaine Injection
Normalized name: articaine Injectable Solution
DrugBank: Articaine (DB09009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic
Study: NCT00180921
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00703898
Drug: nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg/day twice a day
Study: NCT00095069
Drug: MK0928, gaboxadol / Duration of Treatment - 1 year
DrugBank: Gaboxadol (DB06554)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00440258
Drug: Cabergoline
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00442221
Drug: Sumatriptan and Naproxen sodium
Normalized name: sumatriptan and naproxen
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04524884
Drug: Surufatinib
Normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surufatinib is a tablet in the form of 50mg, oral, once a day.
Study: NCT04524884
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
Study: NCT02550717
Drug: Clopidogrel, Oral Anticoagulants, NSAIDs and SSRIs
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Secondary prevention of cardiovascular events
Study: NCT03059667
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab at 1200 mg IV every 3 weeks
Study: NCT03059667
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral 2.3 mg/m² or IV 1.5 mg/m² day 1-4 recommended
Study: NCT03059667
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In accordance with the summary of product characteristics.
Study: NCT03059667
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In accordance with the summary of product characteristics.
Study: NCT01041508
Drug: Clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clofarabine will be given as an intravenous infusion over 2 hours on days -6 though -2. The dose of Clofarabine will be assigned at study entry (30, 40 or 52 mg/m2).
Study: NCT03139500
Drug: JNJ-61803534
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-61803534 tablets orally.
Study: NCT03139500
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive single oral dose of midazolam.
Study: NCT00346866
Drug: anecortave acetate
Normalized name: Anecortave acetate
DrugBank: Anecortave acetate (DB05288)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00268970
Drug: Satraplatin in combination with Paclitaxel
Normalized name: satraplatin
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m2 IV over 3 hours on day 1. Satraplatin 60 mg/m2 administered by mouth once daily for 5 consecutive days (days 1-5). Satraplatin will be administered within 2 hours following paclitaxel infusion on day 1. Subsequent doses on days 2-5 will be taken at approximately 24 hour intervals.
Study: NCT01300572
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO or IV
Study: NCT01300572
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01300572
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO or IV
Study: NCT01791478
Drug: PI3K inhibitor BYL719
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01791478
Drug: letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01369732
Drug: recombinant human erythropoietin
Normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: We administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min before the commencement of ischemia.
Study: NCT01369732
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: We administrate the saline single bolus (5ml intravenously) 30 min before the commencement of ischemia.
Study: NCT00384332
Drug: orally-disintegrating olanzapine
Normalized name: Olanzapine Orally Disintegrating Tablets
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 to 20 mg (daily) orally disintegrating olanzapine for approx.8 weeks.
Study: NCT00384332
Drug: regular olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-20 mg. olanzapine daily for approximately 8 weeks.
Study: NCT01041508
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine is given IV based on body weight at:~* Age ≤ 6 years old: 6 mg/kg IV QD. in divided doses (e.g. 2 mg/kg q8hrs).~* Age \> 6 years old: 3 mg/kg IV QD in divided doses (1.5mg/kg q12hrs)~Cyclosporine should be started on day -1 after completion of Clofarabine. Levels should be maintained between 300-400 ng/ml.
Study: NCT01041508
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MMF will be at 15 mg/kg, based on adjusted body weight, q 8 hours (45 mg/kg/day; max.3g/day) PO, or IV if indicated, from the evening of day 0 (i.e. first dose 4-6 hours following stem cell infusion) to day +40 post-transplant. Oral doses will be rounded to the nearest 250 mg (capsules are 250 mg). MMF is also available in oral suspension form. MMF will be given until day +40 post transplant and then tapered by 10% per week to be discontinued by day +90.
Study: NCT03033121
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01458249
Drug: eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administration of eribulin mesylate at a dose of 1.4 mg/m\^2 as an IV bolus infusion over 2-5 minutes on Days 1 and 8 of every cycle, where the duration of each cycle is 21 days.
Study: NCT00914017
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin, 40 mg daily for 1 year
Study: NCT00962286
Drug: Furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests.Intravenous catheters will be placed in each upper limb for infusion of clearance markers and blood sampling.A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered. Thereafter, inulin and p-aminohippuric acid will be infused continuously. A 200-300 ml water load will be given during the first 60-min prime.~Subjects will be started on furosemide p.o. 20 mg every 12 hours, starting on day 1 at 15.00 after the renal function studies. Nine doses will be taken, the last dose on day 4 at 7 am.~In case the blood pressure does not decrease following 20 mg bid furosemide administration, the study will be repeated after 4 weeks using a dose of 40 mg p.o. bid.
Study: NCT01326585
Drug: Dexamethasone Sodium Phosphate Injection
Normalized name: Dexamethasone Sodium Phosphate Injection
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 8mg (2cc of 4mg/mL solution), IV solution, 1-time dose during surgery
Study: NCT03798236
Drug: PBF-1650 oral capsules
DrugBank: BF-1 (DB06029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine A3 receptor (AA3R) antagonist
Study: NCT01326585
Drug: Saline Injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2cc of 0.9% normal saline, IV injection, 1-time dose during surgery
Study: NCT03606460
Drug: Ocrelizumab Dose 1
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300 mg infusion administered to ocrelizumab-naive participants per approved protocol (over approximately 2.5 hours or longer) as per standard of care followed by a second 300 mg shorter infusion over approximately 1.5 hours.
Study: NCT03606460
Drug: Ocrelizumab Dose 2 and Dose 3
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 600 mg infusion of ocrelizumab administered at a shorter rate (i.e. over the course of approximately 2 hours) at Week 24 and at Week 48
Study: NCT00003377
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003377
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00336895
Drug: Myfortic
Normalized name: Myfortic
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Myfortic 360mg or 720 mg BID for 90 days.
Study: NCT01656382
Drug: ABLC
Normalized name: Chromium Picolinate 200mcg Tablctive Metabolism Tablet
DrugBank: Chromium (DB11136)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01007448
Drug: Bexarotene
Normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Soft gelatin capsules to be taken orally with at least 6 ounces of water or other fluid either with or immediately following the evening meal (a moderate or full meal) or a nutritionally defined liquid food.
Study: NCT01205282
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A modified dose finding method will be used to determine safety and dose response among three dose levels (0.25mg/kg QD, 0.5mg/kg QD, and 0.75mg/kg QD). The dose has been based on the per weight maximum adult dose. Specifically, the FDA has approved 45mg as the maximum adult dose. For a 60kg adult, this is 0.75mg/kg. There will be 14 weeks of active treatment.
Study: NCT03574909
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tromalyt® 150mg prolong release capsule for oral ingestion. The capsule contains 150mg of anti-platelet agent acetylsalicylic acid, maize starch and Sucrose 20:80. The capsule also contains Copovidone (Kollidon VA-64), Eudragit L, Ethylcellulose and Triacetin. The capsule is made with gelatin, erythrosine, quinoline yellow, titanium dioxide.
Study: NCT00126373
Drug: Wellbutrin (bupropion)
Normalized name: bupropion Oral Tablet [Wellbutrin]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupropion 150mg-300mg daily
Study: NCT01442779
Drug: Interferon alpha oral lozenge
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dose form - oral lozenge dose - 150 International Units (IU) frequency - 3 times a day duration - at least 1 year
Study: NCT02991131
Drug: Tedizolid (Sivextro, BAY1192631)
Normalized name: Tedizolid
DrugBank: Tedizolid phosphate (DB09042)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Antibiotic
Study: NCT02991131
Drug: Linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic
Study: NCT00043940
Drug: bivalirudin
Normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bivalirudin therapy will be given as a 0.75-mg/kg intravenous bolus and 1.75-mg/kg/h intravenous infusion during procedure and up to 4 hours.